Akouos to Present at Jefferies Gene Therapy/Editing Summit

Rhea-AI Summary

Akouos, a precision genetic medicine company focused on gene therapies for hearing loss, announced that CEO Manny Simons will present at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 9:30 a.m. EDT. The presentation aims to highlight Akouos's innovative approaches to restoring hearing through its proprietary adeno-associated viral vector library. A live webcast will be available on the company's website, with a replay accessible for 30 days post-conference.

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a presentation at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27 at 9:30 a.m. EDT.

A live webcast of the presentation will be accessible through the investors section of www.akouos.com. To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. An archived replay will be available on Akouos’s website for 30 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

What is Akouos's focus in genetic medicine?

Akouos focuses on developing gene therapies to restore, improve, and preserve hearing for individuals with disabling hearing loss.

When will Manny Simons present at the Jefferies Gene Therapy Summit?

Manny Simons will present on October 27, 2021, at 9:30 a.m. EDT.

How can I access the Akouos presentation at the Jefferies Summit?

You can access the live webcast of the presentation through the investors section of Akouos's website.

Will there be a replay of the Akouos presentation?

Yes, an archived replay of the presentation will be available on Akouos's website for 30 days after the event.

What technology does Akouos use for its therapies?

Akouos leverages a proprietary adeno-associated viral vector library and a novel delivery approach for its gene therapies.